ACIU
OtherAC Immune SA
Live · NASDAQ · May 9, Close
What's Moving ACIU Today?
No stock-specific AI insight has been generated for ACIU yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
ACIU News
20 articles- AC Immune (ACIU) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 30, 2026
- AC Immune First Quarter 2026 Financial and Corporate UpdatesYahoo Finance·Apr 30, 2026
- AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's DiseaseYahoo Finance·Apr 30, 2026
- Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great NewsYahoo Finance·Apr 12, 2026
- ACIU Stock Rallies 16.3% in a Week: Here's What You Need to KnowYahoo Finance·Apr 9, 2026
- Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 9, 2026
- April 2026's Most Promising Penny StocksYahoo Finance·Apr 8, 2026
- Why AC Immune Stock Zoomed Almost 15% Higher TodayMotley Fool·Apr 7, 2026
- Eli Lilly Extends AC Immune Tau Pact To Broaden Alzheimer’s Pipeline PotentialYahoo Finance·Apr 7, 2026
- AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with LillyGlobeNewswire Inc.·Apr 7, 2026
- AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026Yahoo Finance·Mar 19, 2026
- AC Immune (ACIU) Upgraded to Buy: Here's WhyYahoo Finance·Mar 18, 2026
- Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 18, 2026
- AC Immune: Q4 Earnings SnapshotYahoo Finance·Mar 13, 2026
- AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 13, 2026
- AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026Yahoo Finance·Mar 5, 2026
- AC Immune Initiates Phase 1 Clinical Trial of NLRP3 InhibitorYahoo Finance·Feb 24, 2026
- Madrigal sees a stock sell-off; ex-Novartis exec heads to DaiichiBiopharmadive·Feb 20, 2026
- Sector Update: Health Care Stocks Decline Late AfternoonYahoo Finance·Feb 18, 2026
- Top Penny Stocks To Watch In January 2026Yahoo Finance·Jan 13, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.